RxDoctor Payments DataLook up a doctor →

Jodie Harrison

Gerontology · Slidell, LANPI 1063061950

Payments from drug & device makers

$11,866in general payments, 2019–2025

Across 377 payments — averaging $31.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$2K
  • Johnson & Johnson$768
  • E.r. Squibb & Sons, L.L.C.$681
  • AstraZeneca$559
  • Merck$493
  • Astellas Pharma Global Development$443
  • plus $7K from 54 others

What the payments were for

  • Consulting fees$1,15510%
  • Travel & lodging$2392%
  • Food & beverage$9,60081%
  • Education$8727%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Incyte Corporation25$2,231
Johnson & Johnson29$768
E.r. Squibb & Sons, L.L.C.23$681
AstraZeneca(2 entities)18$559
Merck22$493
Astellas Pharma Global Development3$443
Gilead11$437
Adaptive Biotechnologies Corporation4$386
Astellas Pharma US Inc10$372
Novartis28$357
Stemline Therapeutics Inc.11$291
Seagen Inc.8$287
Sanofi-aventis U.S. LLC3$266
AbbVie11$252
Genentech USA, Inc.13$242
Eisai Inc.10$232
Beigene USA, Inc.7$228
Bristol Myers Squibb13$211
Pfizer12$208
Amgen7$208
Regeneron Healthcare Solutions, Inc.10$186
Geron Corporation4$174
Sanofi9$171
Pharmacosmos Therapeutics Inc.3$161
Daiichi Sankyo Inc.7$148
Springworks Therapeutics, Inc.2$139
Puma Biotechnology, Inc.3$126
TG Therapeutics, Inc.1$125
G1 Therapeutics, Inc.3$105
Jazz Pharmaceuticals Inc.5$101
Blueprint Medicines Corporation3$99
Takeda Pharmaceuticals U.S.A., Inc.5$93
Inari Medical, Inc.1$89
GSK5$87
Coherus Oncology, Inc.5$87
Bayer5$85
Pharmacyclics LLC, An Abbvie Company4$76
Janssen Scientific Affairs, LLC1$72
Ipsen Biopharmaceuticals, Inc4$66
Lilly USA, LLC3$63
EMD Serono, Inc.4$56
Progenics Pharmaceuticals, Inc.2$42
Taiho Oncology, Inc.2$37
Kyowa Kirin, Inc.2$36
Rigel Pharmaceuticals, Inc.1$29
Mayne Pharma Commercial LLC1$24
Agios Pharmaceuticals, Inc.1$24
Immunogen, Inc.1$23
Alnylam Pharmaceuticals Inc.1$20
Cumberland Pharmaceuticals, Inc.1$19
ADC Therapeutics America, Inc.1$18
Sobi, Inc1$18
Myriad Genetic Laboratories, Inc.1$17
Tersera Therapeutics LLC1$16
Shield Therapeutics Inc1$16
Apellis Pharmaceuticals, Inc.1$15
Sanofi US Services Inc.1$15
Array Biopharma Inc1$14
Tactile Systems Technology Inc1$14
Morphosys, US Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,866 in reported general payments places this provider in the 95th percentile of 64 gerontology providers in Louisiana.

See all gerontology providers in Louisiana

Medicare billing

Part B allowed, 2024
$23,343
Medicare patients
110
Services billed
349

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide19$275,826
Lenalidomide17$254,957
PromactaEltrombopag Olamine12$221,978
Abiraterone Acetate63$201,232
TagrissoOsimertinib Mesylate11$191,885
VerzenioAbemaciclib11$159,295
EliquisApixaban134$122,247
CreonLipase/Protease/Amylase12$29,832
SancusoGranisetron21$29,529
XareltoRivaroxaban27$28,066
Cyclosporine22$18,024
Letrozole242$4,296
Dabigatran EtexilateDabigatran Etexilate Mesylate13$3,411
Exemestane29$2,950
CholestyramineCholestyramine (With Sugar)11$1,558

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$372$275,82619 claims
NovartisPromacta$357$221,97812 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$72$201,23263 claims
AstraZenecaTagrisso$559$191,88511 claims
Lilly USA, LLCVerzenio$63$159,29511 claims
PfizerEliquis$208$122,247134 claims
AbbVieCreon$252$29,83212 claims
Cumberland Pharmaceuticals, Inc.Sancuso$19$29,52921 claims
Johnson & JohnsonXarelto$768$28,06627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 64 gerontology providers in Louisiana.

Other gerontology in Slidell

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →